GLSI Stock Price, Greenwich LifeSciences, . Quote, Chart

Market Summary

USD14.10+0.11

Market Closed

0.79%

GLSI Alerts

1 major insider buys recently.

GLSI Stock Price

View Fullscreen

GLSI RSI Chart

GLSI Valuation

Market Cap

181.6M

Price/Earnings (Trailing)

-20.42

Price/Free Cashflow

-28.03

GLSI Price/Earnings (Trailing)

GLSI Profitability

Return on Equity

-132.71%

Return on Assets

-127.12%

Free Cashflow Yield

-3.57%

GLSI Fundamentals

GLSI Earnings

Earnings (TTM)

-8.9M

Earnings Growth (Yr)

1.57%

Earnings Growth (Qtr)

-14.84%

Breaking Down GLSI Revenue

Last 7 days

7.5%

Last 30 days

-20.4%

Last 90 days

61.3%

Trailing 12 Months

20.9%

How does GLSI drawdown profile look like?

GLSI Financial Health

Current Ratio

98.18

GLSI Investor Care

Shares Dilution (1Y)

0.24%

Diluted EPS (TTM)

-0.75

Tracking the Latest Insider Buys and Sells of Greenwich LifeSciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	patel snehal	bought	57,240	19.08	3,000	ceo and cfo
Mar 22, 2024	patel snehal	bought	49,950	19.98	2,500	ceo and cfo
Mar 20, 2024	patel snehal	bought	26,520	17.68	1,500	ceo and cfo
Mar 05, 2024	patel snehal	bought	43,715	12.49	3,500	ceo and cfo
Mar 04, 2024	patel snehal	bought	53,423	13.03	4,100	ceo and cfo
Feb 16, 2024	patel snehal	bought	120,528	11.16	10,800	ceo and cfo
Feb 15, 2024	patel snehal	bought	140,589	11.07	12,700	ceo and cfo
Nov 10, 2023	patel snehal	bought	50,837	10.1675	5,000	ceo and cfo
Nov 03, 2023	patel snehal	bought	31,885	9.11	3,500	ceo and cfo
Oct 27, 2023	thompson jaye	bought	4,285	8.57	500	vp clinical reg affairs

Which funds bought or sold GLSI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	North Star Investment Management Corp.	unchanged	-	480	1,017	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	14,130	29,910	0.01%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	1,884	3,988	-%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-526	-	-%
Apr 10, 2024	Founders Capital Management	unchanged	-	4,710	9,970	0.01%
Mar 11, 2024	VANGUARD GROUP INC	added	0.79	387,710	2,332,100	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-405,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	147,333	147,333	-%

Are Funds Buying or Selling GLSI?

Are funds buying GLSI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GLSI

No. of Funds

GLSI Alerts

1 major insider buys recently.

Unveiling Greenwich LifeSciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jun 22, 2022	weiner michael guy	17.7%	2,304,681	SC 13G

Recent SEC filings of Greenwich LifeSciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	10-K	Annual Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	NT 10-K	NT 10-K
Mar 26, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 07, 2024	4/A	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 20, 2024	8-K	Current Report

Peers (Alternatives to Greenwich LifeSciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Greenwich LifeSciences, Inc. News

Latest updates

Greenwich LifeSciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-23.6%	7.00	9.00	11.00	12.00	13.00	16.00	17.00	20.00	27.00	29.00	30.00	30.00	29.00	6.00	-	-	-	-
Current Assets	-	-	-	-	-	-	-	-	-	-	29.00	30.00	30.00	29.00	6.00	-	-	0.00	0.00
Cash Equivalents	-23.6%	7.00	9.00	11.00	12.00	13.00	16.00	17.00	20.00	27.00	29.00	30.00	30.00	29.00	6.00	-	-	0.00	0.00
Liabilities	-1.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	10.00
Current Liabilities	-1.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	2.00	-	-	1.00	1.00
Shareholder's Equity	-24.3%	7.00	9.00	11.00	12.00	13.00	15.00	17.00	20.00	27.00	28.00	29.00	30.00	28.00	5.00	-	-	-	-
Retained Earnings	-5.8%	-50.36	-47.62	-45.23	-43.60	-41.47	-38.68	-36.36	-35.62	-33.65	-31.29	-30.42	-29.67	-29.08	-27.93	-	-	-27.21	-23.79
Additional Paid-In Capital	1.1%	57.00	56.00	56.00	55.00	55.00	54.00	53.00	55.00	60.00	60.00	60.00	59.00	57.00	33.00	-	-	26.00	14.00
Shares Outstanding	0%	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	-	-	-	-	-	-
Float	-	-	-	57.00	-	-	-	49.00	-	-	-	171	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-19.6%	-2,154	-1,800	-966	-1,556	-2,170	-1,549	-532	-1,947	-2,264	-894	-604	-528	-	-	-	-
Share Based Compensation	0%	595	595	595	595	595	760	225	165	165	165	165	165	165	-	-	-
Cashflow From Financing	-	-	-	-	-	-	-	-2,022	-5,513	563	-	-	2,273	23,599	-	-	-
Buy Backs	-	-	-	-	-	-	-	2,023	5,514	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GLSI Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue
Operating expenses
Research and development	7,698,622	6,475,668
General and administrative	1,629,244	1,564,586
Total operating expenses	9,327,866	8,040,254
Loss from operations	(9,327,866)	(8,040,254)
Interest income	436,063	215,017
Net loss	$ (8,891,803)	$ (7,825,237)
Per share information:
Net loss per common share, basic	$ (0.69)	$ (0.61)
Net loss per common share, diluted	$ (0.69)	$ (0.61)
Weighted average common shares outstanding, basic	12,848,165	12,913,848
Weighted average common shares outstanding, diluted	12,848,165	12,913,848

GLSI Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 6,989,424	$ 13,468,026
Acquired patents, net	5,391	9,003
Total assets	6,994,815	13,477,029
Current liabilities
Accounts payable & accrued interest	256,317	220,845
Unreimbursed expenses	38,089	42,060
Total current liabilities	294,406	262,905
Total liabilities	294,406	262,905
Stockholders’ equity
Common stock, $0.001 par value; 100,000,000 shares authorized; 12,848,165 shares issued and outstanding as of December 31, 2023 and 2022	12,848	12,848
Additional paid-in capital	57,052,130	54,674,042
Accumulated deficit	(50,364,569)	(41,472,766)
Total stockholders’ equity	6,700,409	13,214,124
Total liabilities and stockholders’ equity	$ 6,994,815	$ 13,477,029

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

CEO	Mr. Snehal S. Patel
WEBSITE	https://greenwichlifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	3

Greenwich LifeSciences, Inc. Frequently Asked Questions

What is the ticker symbol for Greenwich LifeSciences, Inc.? What does GLSI stand for in stocks?

GLSI is the stock ticker symbol of Greenwich LifeSciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Greenwich LifeSciences, Inc. (GLSI)?

As of Fri May 03 2024, market cap of Greenwich LifeSciences, Inc. is 181.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLSI stock?

You can check GLSI's fair value in chart for subscribers.

What is the fair value of GLSI stock?

You can check GLSI's fair value in chart for subscribers. The fair value of Greenwich LifeSciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Greenwich LifeSciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GLSI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Greenwich LifeSciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether GLSI is over valued or under valued. Whether Greenwich LifeSciences, Inc. is cheap or expensive depends on the assumptions which impact Greenwich LifeSciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLSI.